Zenas BioPharma is a clinical-stage biopharmaceutical company developing immunology-based therapies for autoimmune diseases, led by experienced management and biopharmaceutical networks. Its lead program, obexelimab, is a bifunctional monoclonal antibody that reversibly inhibits B cell activity to treat conditions including immunoglobulin G4-related disease, multiple sclerosis, and systemic lupus erythematosus. The company also develops additional candidates including a CNS-penetrant BTK inhibitor and oral IL-17 and TYK2 inhibitors, primarily licensed from InnoCare. Zenas has no current product sales but plans to generate revenue through product sales in developed markets, strategic partnerships for geographic expansion, and milestone and royalty payments from existing licensing agreements with partners including Bristol Myers Squibb.